Cadrenal Therapeutics, Inc. (CVKD) AI Stock Analysis

• Market Cap: $32.82M
• Dividend Yield: N/A
• Average Volume (3M): 39.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: N/A
• EPS Growth: 16.20%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): -8.73
• Shares Outstanding: 1,879,710
• 10 Day Avg. Volume: 24,676
• 30 Day Avg. Volume: 39,811
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -5.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $45.00
• Price Target Upside: 157.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Cadrenal Therapeutics, Inc. faces significant financial challenges with no revenue generation and consistent losses, heavily relying on financing activities. Technical analysis suggests neutral momentum with some downward pressure, while valuation metrics are hampered by negative earnings. The recent corporate event of appointing a new Chief Medical Officer could be promising for future clinical developments but does not immediately alter the financial outlook. Overall, the stock is rated low due to the pressing financial sustainability concerns.

Cadrenal Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Cadrenal Therapeutics, Inc. (CVKD) is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of cardiovascular diseases. The company is dedicated to addressing unmet medical needs by advancing innovative solutions that improve patient outcomes. Its core product offerings typically revolve around proprietary drug formulations and therapeutic interventions aimed at treating specific cardiac-related conditions.

How the Company Makes Money

Cadrenal Therapeutics makes money primarily through the development and commercialization of proprietary pharmaceuticals. Revenue is generated from the sale of these drugs once they receive regulatory approval and are brought to market. Additionally, the company may engage in strategic partnerships and collaborations with other pharmaceutical firms, which can provide additional revenue streams through licensing agreements, milestone payments, and royalties. These partnerships can also help Cadrenal Therapeutics expand its market reach and accelerate the development of its product pipeline.

Cadrenal Therapeutics, Inc. Financial Statement Overview

Summary

Cadrenal Therapeutics, Inc. faces financial challenges with no revenue generation and consistent losses over the past three years. The company relies heavily on financing to maintain operations, with no clear path to revenue or profit generation. While the absence of debt is a positive factor, the lack of operational cash flow and ongoing losses are key concerns for long-term sustainability.

Income Statement

Cadrenal Therapeutics, Inc. has reported zero revenue over the past three years, indicating no operational sales or income. The company consistently reports negative EBIT and net income, highlighting ongoing operational losses without any revenue growth trajectory.

Balance Sheet

The company's balance sheet shows improvement in equity from negative to positive values, mainly due to financing activities. However, there is a lack of revenue generation and reliance on external financing. The absence of debt is positive, but the company is not generating income to strengthen its financial position.

Cash Flow

Cadrenal Therapeutics, Inc. shows negative free cash flow, indicating cash outflows exceeding inflows from operations. Operating cash flows are negative and increasing in magnitude, primarily supported by financing cash inflows. There is no cash flow generated from operations, posing sustainability challenges.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
2.77K	0.00	0.00	0.00
	Gross Profit
1.10K	0.00	-1.98K	-1.27K
	EBIT
-7.95M	-10.96M	-7.63M	-2.70M
	EBITDA
-7.66M	-10.96M	-8.34M	-6.61M
	Net Income Common Stockholders
-7.61M	0.00	-8.36M	-6.71M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
32.59K	10.02M	8.40M	32.59K
	Total Assets
778.17K	10.12M	8.52M	778.17K
	Total Debt
640.71K	0.00	21.35K	640.71K
	Net Debt
608.12K	-10.02M	-8.38M	608.12K
	Total Liabilities
6.33M	2.68M	826.88K	6.33M
	Stockholders Equity
-5.55M	7.44M	7.69M	-5.55M
Cash Flow		Free Cash Flow
-6.26M	-7.36M	-3.53M	-1.20M
	Operating Cash Flow
-6.26M	-7.36M	-3.53M	-1.20M
	Investing Cash Flow
1.00	-6.54K	-3.25K	-2.28K
	Financing Cash Flow
1.52M	8.98M	11.90M	1.24M

Cadrenal Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVKD, the sentiment is Negative. The current price of 17.46 is below the 20-day moving average (MA) of 18.25, below the 50-day MA of 18.71, and above the 200-day MA of 13.29, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.55 is Neutral, neither overbought nor oversold. The STOCH value of 25.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVKD.

Cadrenal Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	70 Outperform	$1.11B	212.18	1.52%	―	33.97%	―
FOLD	61 Neutral	$2.44B	―	-31.68%	―	32.29%	64.39%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
ENTA	46 Neutral	$113.49M	―	-69.10%	―	-9.55%	24.57%
AMRN	42 Neutral	$181.92M	―	-15.79%	―	-25.86%	-37.14%
KZR	41 Neutral	$32.95M	―	-55.00%	―	-100.00%	18.17%
CVKD	39 Underperform	$32.82M	―	-140.78%	―	―	16.20%

Cadrenal Therapeutics, Inc. Corporate Events

Cadrenal Therapeutics Appoints New Chief Medical Officer

On February 4, 2025, Cadrenal Therapeutics, Inc. appointed Dr. James J. Ferguson as its new Chief Medical Officer, effective February 5, 2025, following the mutually amicable departure of Dr. Douglas Losordo. Dr. Ferguson, with extensive experience in cardiovascular medicine, will lead the late-stage clinical development of tecarfarin, including a pivotal Phase 3 trial for LVAD patients. This leadership transition is expected to strengthen Cadrenal’s efforts in addressing unmet medical needs associated with standard warfarin therapy and enhance its pipeline of specialized cardiovascular treatments.